A new report commissioned by NHS England (NHSE): Evaluating Pathways for AI Dermatology in Skin Cancer Detection states Skin Analytics’ Artificial Intelligence as a Medical Device (AIaMD), DERM, can be used autonomously in the NHS.
With a 300% increase in urgent suspected skin cancer referrals since 2010 and 45-50 patients seen per day at the Skin Cancer Centre in Amersham Hospital, Buckinghamshire Healthcare NHS Trust implements DERM to address their increasing dermatology demand.
Join us for an interactive webinar hosted by Convenzis that delves into the pioneering integration of AI in dermatology within the NHS Wednesday 18th September
Yesterday evening, some of the Skin Analytics team attended the MelaNoMore Summer BBQ in Guildford. We were grateful to be invited back for a third time and given the opportunity to speak.
Skin Analytics joins the Royal Society of Medicine, Digital Health Section podcast to discuss all things post-market surveillance.
Chelsea and Westminster Hospital NHS Foundation Trust (CWFT) and NHS Suffolk and North East Essex Integrated Care Board (SNEE) have been shortlisted for the HSJ Awards 2024, recognising an outstanding contribution to healthcare and securing a place at the prestigious awards ceremony later this year.
Last month, Alastair Fee, reporter at the BBC, visited UHD’s dermatology department at Christchurch to see how our AI as a medical device is being used to drive quicker access to skin cancer diagnosis for patients in the locality and reduce waiting times.
It’s AI Appreciation Day so we’re celebrating the human behind our AI as a medical device – Dr Jack Greenhalgh, Skin Analytics’ AI Director.
Nestled in the historical arches beneath Manchester Central at Three Little Words, we welcomed like-minded individuals across the NHS to hear from Dr Justin M Ko, Dr Julia Schofield, Dr Lucy Thomas and Dr Dilraj Kalsi.
Tameside and Gloosop Integrated Care NHS Foundation Trust are a General Manchester based trust who are opening their doors again to urgent suspected skin cancer referrals – only this time the post-referral service will use AI Teledermatology.
In mid May 2024, TechRound ran their first AITech35 campaign, celebrating the most exciting AI companies and innovations across the UK and Europe. As a hugely popular and fast-growing market, TechRound felt compelled to launch a competition showcasing the best in AI. With 35 positions up for grabs, we’re proud to be positioned as number 5.
Manchester University NHS Foundation Trust launches a post-referral service for suspected skin cancer with Skin Analytics.
People passionate about building a world where no one dies from skin cancer, all in one room at the Skin Analytics Customer Conference!
Skin Analytics challenge the team to 31 days of wearing 30+ SPF for Skin Cancer Awareness Month.
The Skin Analytics team were delighted to be one of the leaders at the frontline of digital healthcare transformation sharing our insight and real-world impact at The Digital Healthcare Show 2024.
We were so proud to be nominated for the Health Tech Company of the Year award, celebrating established companies helping to set the blueprint for health tech success in 2024.
By leveraging our AI medical device, DERM, within UHD’s post-referral pathway, we will look to address the gap between demand and capacity so the Trust’s dermatologists can spend precious time on patients who need them most.
With extremely limited dermatology capacity resulting in all Trust resources consumed by efforts to meet FDS targets, this AI powered pathway will remove the need to see patients with benign lesions face-to-face and reserve Dorset County Hospital’s dermatology capacity for patients with skin cancer.
Rishi Sunak and Skin Analytics were invited to a meet and greet at Woking Community Hospital to see the work being delivered at Woking Community Centre’s Diagnostic Hub.
LUHFT are one of the additional nine NHS trusts awarded funding to pilot DERM, and their patients in the Sefton area will be first out of approximately 45,000 patients to benefit from our technology by the summer – when skin cancer referrals are at their highest.
An additional nine NHS trusts have been funded to pilot Skin Analytics’ AI medical device to detect cancerous skin lesions, with around 45,000 patients benefiting from this groundbreaking technology by the summer when skin cancer referrals are at their highest.
Now a Class IIa medical device, DERM, uses machine learning algorithms to recognise the most common malignant, pre-malignant and benign skin lesions, including melanoma – the fifth most common cancer in the UK. Using a decade’s worth of research and development on skin lesions, it is designed to accelerate patient diagnosis and relieve pressure on the healthcare system.
We were delighted to see research into the publicly available skin cancer datasets many use to train AI systems to assess skin cancer published in The Lancet Digital Health last week.
Applying academic rigour to a long known issue around machine learning helps to educate the industry around one of the foundations on which AI systems are built; training data.
Created to accelerate the evaluation of Artificial Intelligence (AI) technologies within the NHS, the NHSX award is highly competitive and prestigious, with an extensive evaluation process. Being granted the award is a major validation of what we do at Skin Analytics and the effort we have put in to build strong foundations based on clinical evidence, regulatory rigor and proprietary AI.
Google’s announcement of the culmination of three years of work and a subsequent move into skin disease analysis at their developer conference earlier this week has led to a number of people approaching me to ask what does this mean for Skin Analytics?
In this blog as Medical Director of Skin Analytics, I wanted to share with the wider dermatology community our position regarding our regulatory status and why you can safely deploy our medical device DERM.
We believe that all responsible AI companies providing services to the healthcare sector should comply with the code of conduct and we have written our response to the NHS AI Code of Conduct.
ISO 13485:2016 is an internationally recognised quality standard for medical devices and is a pre-requisite for registration as a class II medical device under the MDR. This accreditation represents another important milestone for the company and our mission to help more people survive skin cancer.
In February 2020, skin cancer researchers released a paper calling into question…
The prospective, diagnostic trial saw DERM, our AI platform, correctly identify all malignant lesions (100% sensitivity) with an average AUROC of 95.8% with 65% specificity versus 70% specificity and a 77% AUROC score demonstrated by the clinical experts. DERM, a CE marked medical device, was developed as a tool to aid clinicians in identifying 11 common skin lesion types, including melanoma.
